Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR | P30968 | 7/20 | 0.54 |
| ▸ | HTR1A | P08908 | 2/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.45 |
| ▸ | DRD2 | P14416 | 5/20 | 0.44 |
| ▸ | DRD3 | P35462 | 4/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | VCP | P55072 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2157285 | 0.76 | KDM4E (0.55) | RXFP1EPHX2DRD2DRD3ABCB1 | |
| SCHEMBL30824828 | 0.76 | RXFP1 (0.52) | RXFP1EPHX2DRD2DRD3ABCB1 | |
| SCHEMBL27390612 | 0.76 | RXFP1 (0.52) | RXFP1EPHX2DRD2DRD3ABCB1 | |
| SCHEMBL16676642 | 0.76 | RXFP1 (0.61) | HTR1ARXFP1EPHX2DRD2DRD3 | |
| SCHEMBL29079559 | 0.74 | EPHX2 (0.50) | RXFP1EPHX2ABCB1 | |
| SCHEMBL29768191 | 0.74 | EPHX2 (0.50) | RXFP1EPHX2ABCB1 | |
| SCHEMBL5524088 | 0.73 | GNRHR (0.64) | GNRHRHTR1ADRD2DRD3DRD4 | |
| SCHEMBL18135536 | 0.73 | KCNA5 (0.64) | EPHX2DRD2DRD3 | |
| SCHEMBL16674535 | 0.73 | RXFP1 (0.56) | RXFP1EPHX2DRD2DRD3ABCB1 | |
| SCHEMBL2165368 | 0.73 | SQOR (0.55) | RXFP1EPHX2DRD2DRD3ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1814866-A2 | GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006058012-A2 | GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS | WYETH (US) | 2006-06-01 | — | — | WO | disclosed |
| US-20060111355-A1 | Gonadotropin releasing hormone receptor antagonists | WYETH (US) | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111355-A1 | Gonadotropin releasing hormone receptor antagonists | GNRHR, LHCGR, GHRHR | GNRHR 1/4885HTR1A 339/4885RXFP1 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.